CTC and AR-V7 analysis in the ECOG-ACRIN 8153 (CHAARTED2) randomized trial: Abiraterone (Abi) with or without cabazitaxel (Abi-Cabazi) in extensive mCRPC following docetaxel.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Christos Kyriakopoulos, Yu-Hui Chen, Robert Jeraj, Fenghai Duan, Abhishek Tripathi, David Kosoff, Rohan Garje, Russell Kent Pachynski, Rahul Atul Parikh, Andrea Harzstark, Nabil Adra, Benjamin L. Maughan, Yousef Zakharia, Paul Gettys Corn, Glenn Liu, Michael A Carducci, Jun Luo, Emmanuel S. Antonarakis
Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Dana-Farber Cancer Institute, Brown University, City Of Hope National Medical Center, Baptist Hospital of Miami, Baptist Health South Florida, Washington University in St. Louis, Alvin J. Siteman Cancer Center, The University of Kansas Cancer Center, Kaiser Permanente, Kaiser Permanente San Francisco Medical Center, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Huntsman Cancer Institute, University of Iowa Holden Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Minnesota, Masonic Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407701471